Modeling interchild differences in pharmacokinetics on the basis of subject-specific data on physiology and hepatic CYP2E1 levels: A case study with toluene

Toxicology and Applied Pharmacology

Volumn 214, Issue 1, 2006, Pages 78-87

  Nong, A ^a   McCarver, D G ^b   Hines, R N ^b   Krishnan, K ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Child; CYP2E1; Interindividual variability; PBPK model

Indexed keywords

CYTOCHROME P450 2E1; LIVER ENZYME; TOLUENE; VOLATILE AGENT;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; AUTOPSY; BLOOD; BLOOD SAMPLING; BODY WEIGHT; CALCULATION; CHILD; DATA ANALYSIS; FEASIBILITY STUDY; FEMALE; HUMAN; HUMAN TISSUE; INFANT; INHALATION; LIVER METABOLISM; LIVER WEIGHT; MALE; METHODOLOGY; NEWBORN; NEWBORN PERIOD; PARAMETER; PHYSICAL CHEMISTRY; RISK ASSESSMENT; VENOUS BLOOD; VOLUNTEER;

EID: 33744983317     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2005.12.001     Document Type: Article

References (58)

1. Agency for Toxic Substances and Disease Registry (ATSDR). Toxicological Profile for Toluene (2000), U.S. Department Of Health And Human Services, Atlanta, GA
2. American Conference of Governmental Industrial Hygienists (ACGIH). The Documentation of the Threshold Limit Values and Biological Exposure Indices (2005), ACGIH, Cincinnati, OH
3. Benignus V.A., Bushnell P.J., and Boyes W.K. A dosimetric analysis of behavioral effects of acute toluene exposure in rats and humans. Toxicol. Sci. 43 (1998) 186-195
4. Benignus V.A., Bushnell P.J., and Boyes W.K. Toward cost-benefit analysis of acute behavioral effects of toluene in humans. Risk Anal. 25 (2005) 447-456
5. Cahalan M.K., Johnson B.H., and Edger E.I. Relationship of concentrations of halothane and enflurane to their metabolism and elimination in man. Anesthesiology 54 (1981) 3-8
6. Clewell H.J., and Andersen M.E. Use of physiologically based pharmacokinetic modeling to investigate individual versus population risk. Toxicology 111 (1996) 315-329
7. Clewell H.J., Teeguarden J., McDonald T., Sarangapani R., Lawrence G., Covington T., Gentry R., and Shipp A. Review and evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry. Crit. Rev. Toxicol. 32 (2002) 329-389
8. Clewell H.J., Gentry P.R., Covington T.R., Sarangapani R., and Teeguarden J.G. Evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry. Toxicol. Sci. 79 (2004) 381-393
9. Cresteil T. Onset of xenobiotic metabolism in children: toxicological implications. Food Addit. Contam. 15 (1998) 45-51 (Suppl.)
10. Delic J.I., Lilly P.D., MacDonald A.J., and Loizou G.D. The utility of PBPK in the safety assessment of chloroform and carbon tetrachloride. Regul. Toxicol. Pharmacol. 32 (2000) 144-155
11. Dorne J.L., and Renwick A.G. The refinement of uncertainty/safety factors in risk assessment by the incorporation of data on toxicokinetic variability in humans. Toxicol. Sci. 86 (2005) 20-26
12. Dorne J.L., Walton K., and Renwick A.G. Human variability in xenobiotic metabolism and pathway-related uncertainty factors for chemical risk assessment: a review. Food Chem Toxicol. 43 (2005) 203-216
13. Dourson M., Charnley G., and Scheuplein R. Differential sensitivity of children and adults to chemical toxicity: II. Risk and regulation. Regul. Toxicol. Pharmacol. 35 (2002) 448-467
14. Foo S.C., Jeyaratnam J., and Koh D. Chronic neurobehavioral effects of toluene. Br. J. Ind. Med. 47 (1990) 480-484
15. Gentry P.R., Covington T.R., and Clewell H.J. Evaluation of the potential impact of pharmacokinetic differences on tissue dosimetry in offspring during pregnancy and lactation. Regul. Toxicol. Pharmacol. 38 (2003) 1-16
16. Ginsberg G., Hattis D., Russ A., and Sonawane B. Physiologically based pharmacokinetic (PBPK) modeling of caffeine and theophylline in neonates and adults: implications for assessing children's risks from environmental agents. J. Toxicol. Environ. Health 27 (2004) 297-329
17. Guengerich F.P., Kim D.H., and Iwasaki M. Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem. Res. Toxicol. 4 (1991) 168-179
18. Haddad S., Pelekis M., and Krishnan K. A methodology for solving physiologically based pharmacokinetic models without the use of simulation softwares. Toxicol. Lett. 85 (1996) 113-126
19. Haddad S., Tardif R., Viau C., and Krishnan K. A modeling approach to account for pharmacokinetic interactions in the calculation of biological hazard index for chemical mixtures. Toxicol. Lett. 108 (1999) 303-308
20. Haddad S., Restieri C., and Krishnan K. Characterization of age-related changes in body weight and organ weights from birth to adolescence in humans. J. Toxicol. Environ. Health, Part A 64 (2001) 453-464
21. International Program on Chemical Safety (IPCS). Guidance Document for the Use of Data in Development of Chemical-Specific Adjustment Factors (CSAFs) for Interspecies Differences and Human Variability in Dose/Concentration-Response Assessment (2001), World Health Organization, Geneva
22. Jarabek A.M. The application of dosimetry models to identify key processes and parameters for default dose-response assessment approaches. Toxicol. Lett. 79 (1995) 171-184
23. Johnsrud E.K., Koukouritaki S.B., Divakaran K., Brunengraber L.L., Hines R.N., and McCarver D.G. Human hepatic CYP2E1 expression during development. J. Pharmacol. Exp. Ther. 307 (2003) 402-407
24. Jonsson F., and Johanson G. Bayesian estimation of variability in adipose tissue blood flow in man by physiologically based pharmacokinetic modeling of inhalation exposure to toluene. Toxicology 157 (2001) 177-193
25. Jonsson F., and Johanson G. Physiologically based modeling of the inhalation kinetics of styrene in humans using a Bayesian population approach. Toxicol. Appl. Pharmacol. 179 (2002) 35-49
26. Kao S.C., Bell E.F., Brown B.P., and Smith W.L. Duplex Doppler sonography of changes in portal vein flow in healthy term newborn infants after feeding. J. Ultrasound Med. 15 (1996) 121-125
27. Kedderis G.L., and Lipscomb J.C. Application of in vitro biotransformation data and pharmacokinetic modeling to risk assessment. Toxicol. Ind. Health 17 (2001) 315-321
28. Koukouritaki S.B., Manro J.R., Marsh S.A., Stevens J.C., Rettie A.E., McCarver D.G., and Hines R.N. Developmental expression of human hepatic CYP2C9 and CYP2C19. J. Pharmacol. Exp. Ther. 308 (2004) 965-974
29. Lipscomb J.C., Teuschler L.K., Swartout J., Popken D., Cox T., and Kedderis G.L. The impact of cytochrome P450 2E1-dependent metabolic variance on a risk-relevant pharmacokinetic outcome in humans. Risk Anal. 23 (2003) 1221-1238
30. Lipscomb J.C., Barton H.A., Tornero-Velez R., Evans M.V., Alcasey S., Snawder J.E., and Laskey J. The metabolic rate constants and specific activity of human and rat hepatic cytochrome P-450 2E1 toward toluene and chloroform. J. Toxicol. Environ. Health, Part A 67 (2004) 537-553
31. Lof A., Wigaeus Hjelm E., Colmsjo A., Lundmark B.O., Norstrom A., and Sato A. Toxicokinetics of toluene and urinary excretion of hippuric acid after human exposure to 2H8-toluene. Br. J. Ind. Med. 50 (1993) 55-59
32. Nakajima T., and Wang R.S. Induction of cytochrome P450 by toluene. Int. J. Biochem. 26 (1994) 1333-1340
33. Nakajima T., Elovaara E., Park S.S., Gelboin H.V., and Vainio H. Immunochemical detection of cytochrome P450 isozymes induced in rat liver by n-hexane, 2-hexanone and acetonyl acetone. Arch. Toxicol. 65 (1991) 542-547
34. Nakajima T., Wang R.S., Elovaara E., Gonzalez F.J., Gelboin H.V., Raunio H., Pelkonen O., Vainio H., and Aoyama T. Toluene metabolism by cDNA-expressed human hepatic cytochrome P450. Biochem. Pharmacol. 53 (1997) 271-277
35. Nakamura H., Tanaka E., Ishikawa A., Fukao K., Tsuji K., and Ohkawa H. Age-related changes in hepatic drug-oxidizing activity using trimethadione as a probe drug in humans. Hepatol. Res. 12 (1998) 85-92
36. National Toxicology Program (NTP), 1990. Toxicology and Carcinogenesis Studies of Toluene (CAS No. 108-88-3) in F344/N Rats and B5C3F1 Mice (Inhalation Studies). Public Health Service, U.S. Department of Health and Human Services; NTP TR 371.
37. Ogata M. Estimation of solvent concentrations in ambient air from urinary metabolite levels of workers exposed to solvents. Ind. Health 22 (1984) 319-324
38. Pierce C.H., Dills R.L., Silvey G.W., and Kalman D.A. Partition coefficients between human blood or adipose tissue and air for aromatic solvents. Scand. J. Work, Environ. Health 22 (1996) 112-118
39. Poulin P., and Krishnan K. Molecular structure-based prediction of the toxicokinetics of inhaled vapors in humans. Int. J. Toxicol. 18 (1999) 7-18
40. Price K., Haddad S., and Krishnan K. Physiological modeling of age-specific changes in the pharmacokinetics of organic chemicals in children. J. Toxicol. Environ. Health, Part A 66 (2003) 417-433
41. Price P.S., Conolly R.B., Chaisson C.F., Gross E.A., Young J.S., Mathis E.T., and Tedder D.R. Modeling interindividual variation in physiological factors used in PBPK models of humans. Crit. Rev. Toxicol. 33 (2003) 469-503
42. Rumchev K., Spickett J., Bulsara M., Phillips M., and Stick S. Association of domestic exposure to volatile organic compounds with asthma in young children. Thorax 59 (2004) 746-751
43. Sexton K., Adgate J.L., Church T.R., Ashley D.L., Needham L.L., Ramachandran G., Frederickson A.L., and Ryan A.D. Children's exposure to volatile organic compounds as determined by longitudinal measurements in blood. Environ. Health Perspect. 113 (2005) 342-349
44. Sonnier M., and Cresteil T. Delayed ontogenesis of CYP1A2 in the human liver. Eur. J. Biochem. 251 (1998) 893-898
45. Stevens J.C., Hines R.N., Gu C., Koukouritaki S.B., Manro J.R., Tandler P.J., and Zaya M.J. Developmental expression of the major human hepatic CYP3A enzymes. J. Pharmacol. Exp. Ther. 307 (2003) 573-582
46. Sweeney L.M., Tyler T.R., Kirman C.R., Corley R.A., Reitz R.H., Paustenbach D.J., Holson J.F., Whorton M.D., Thompson K.M., and Gargas M.L. Proposed occupational exposure limits for select ethylene glycol ethers using PBPK models and Monte Carlo simulations. Toxicol. Sci. 62 (2001) 124-139
47. Sweeney L.M., Kirman C.R., Morgott D.A., and Gargas M.L. Estimation of interindividual variation in oxidative metabolism of dichloromethane in human volunteers. Toxicol. Lett. 154 (2004) 201-216
48. Tanaka E. Clinically important pharmacokinetic drug-drug interactions: role of cytochrome P450 enzymes. J. Clin. Pharm. Ther. 23 (1998) 403-416
49. Tardif R., Lapare S., Charest-Tardif G., Brodeur J., and Krishnan K. Physiologically-based pharmacokinetic modeling of a mixture of toluene and xylene in humans. Risk Anal. 15 (1995) 335-342
50. Tardif R., Charest-Tardif G., Brodeur J., and Krishnan K. Physiologically based pharmacokinetic modeling of a ternary mixture of alkyl benzenes in rats and humans. Toxicol. Appl. Pharmacol. 144 (1997) 120-134
51. Tardif R., Truchon G., and Brodeur J. Comparison of hippuric acid and o-cresol in urine and unchanged toluene in alveolar air for the biological monitoring of exposure to toluene in human volunteers. Appl. Occup. Environ. Hyg. 13 (1998) 127-132
52. Tassaneeyakul W., Birkett D.J., Edwards J.W., Veronese M.E., Tassaneeyakul W., Tukey R.H., and Miners J.O. Human cytochrome P450 isoform specificity in the regioselective metabolism of toluene and o-, m- and p-xylene. J. Pharmacol. Exp. Ther. 276 (1996) 101-108
53. Thomas R.S., Bigelow P.L., Keefe T.J., and Yang R.S. Variability in biological exposure indices using physiologically based pharmacokinetic modeling and Monte Carlo simulation. Am. Ind. Hyg. Assoc. J. 57 (1996) 23-32
54. US Environmental Protection Agency (USEPA), 2001. Risk Assessment Guidance for Superfund Volume 3 Part A: Process for Conducting Probabilistic Risk Assessment (RAGS 3A). Office of Research and Development. USEPA, Washington, DC. EPA/540/R-02/002.
55. US Environmental Protection Agency (USEPA), 2005. Toxicological Review of Toluene in Support of Summary Information on the Integrated Risk Information System (IRIS). USEPA, Washington, DC. EPA/635/R-05/004.
56. Vieira I., Sonnier M., and Cresteil T. Developmental expression of CYP2E1 in the human liver. Hypermethylation control of gene expression during the neonatal period. Eur. J. Biochem. 238 (1996) 476-483
57. White D.R., Widdowson E.M., and Woodard H.Q. The composition of body tissues. (II) Fetus to young adult. Br. J. Radiol. 64 (1991) 149-159
58. Wilkinson G.R., and Shand D.G. Commentary: a physiological approach to hepatic drug clearance. Clin. Pharmacol. Ther. 18 (1975) 377-390